
Ascletis Advances Oral Obesity Pill Combining GLP-1R and GIPR Agonists
Hong Kong-based Ascletis Pharma is moving toward human clinical trials for a once-daily, two-in-one oral tablet designed to treat obesity by targeting both GLP-1R and GIPR pathways, a mechanism similar to the market-leading injectable tirzepatide.






















